The role of hormonal and nutritional biomarkers in predicting immune checkpoint inhibitor efficacy: current limitations and future prospects
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet durable benefit remains limited to selected patients. Established biomarkers, including PD-L1 expression, tumor mutational burden, and microsatellite instability, remain predomi…